Unknown

Dataset Information

0

Evaluation of several botulinum toxins-A delivering systems into the bladder in interstitial cystitis/painful bladder syndrome (IC/PBS).


ABSTRACT: Botulinum toxins were primary suggested for the neurogenic lower urinary tract dysfunction (LUTD) treatment about thirty years ago. The application of BTX-A in LUTD have just developed and the approval of BTX-A injection confirmed in for patients with both overactive bladders (OAB) and neurogenic detrusor overactivity (NDO). Actually the BTX-A medication in interstitial cystitis/bladder pain syndrome (IC/BPS) is not licensed, but there is under consideration. Despite BTX-A is recommended to treat patients with interstitial cystitis/bladder pain syndrome (ICBPS) under different occasions, its efficacy and safety in the cure of (IC/BPS) is under consideration. One difficulty is related to the toxin delivering systems. It is shown that there is no difference in BTX-A injection to body or trigone but there is a need on further large-scale studies over this subject. Moreover, Hydro distention can boost the therapeutic effect of BTX-A for IC/BPS patients. Additional studies should consider the safety and efficacy of BTX-A injection in the treatment of BTX-A.

SUBMITTER: Torkamand F 

PROVIDER: S-EPMC6872472 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of several botulinum toxins-A delivering systems into the bladder in interstitial cystitis/painful bladder syndrome (IC/PBS).

Torkamand Farbod F   Mirjavadi Seyed Javad SJ   Khatami Fatemeh F   Guitynavard Fateme F   Aghamir Seyed Mohammad Kazem SMK  

American journal of clinical and experimental urology 20191025 5


Botulinum toxins were primary suggested for the neurogenic lower urinary tract dysfunction (LUTD) treatment about thirty years ago. The application of BTX-A in LUTD have just developed and the approval of BTX-A injection confirmed in for patients with both overactive bladders (OAB) and neurogenic detrusor overactivity (NDO). Actually the BTX-A medication in interstitial cystitis/bladder pain syndrome (IC/BPS) is not licensed, but there is under consideration. Despite BTX-A is recommended to trea  ...[more]

Similar Datasets

| S-EPMC3256302 | biostudies-literature
| S-EPMC6459590 | biostudies-literature
| S-EPMC3519367 | biostudies-literature
| S-EPMC2861998 | biostudies-literature
| S-EPMC6815247 | biostudies-literature
| S-EPMC10461181 | biostudies-literature
| S-EPMC10868762 | biostudies-literature
| S-EPMC10891743 | biostudies-literature
| S-EPMC4152268 | biostudies-other
| S-EPMC3408599 | biostudies-literature